Ocata receives patents for retinal pigment epithelium transplant technology

Ocata Therapeutics has received three new U.S. patents that expand the scope of earlier patents for retinal pigment epithelium transplant technology, according to a company press release.The expanded patent protection includes “all formats and formulations of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents, and the use of these formulations for treating ophthalmic diseases such as dry age related macular degeneration and Stargardt’s macular degeneration,” according to the release.